A retrospective study on the influence of nutritional status on pain management in cancer patients using the transdermal fentanyl patch

Biological and Pharmaceutical Bulletin

Volumn 37, Issue 5, 2014, Pages 853-857

  Takahashi, Hiroaki ^a   Chiba, Takeshi ^a   Tairabune, Tomohiko ^a   Kimura, Yusuke ^a   Wakabayashi, Go ^a   Takahashi, Katsuo ^a   Kudo, Kenzo ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

Fentanyl patch; Nutrition Risk Screening 2002; Nutritional status; Pain control

Indexed keywords

DUROTEP; FENTANYL; FENTOS; ONEDURO; OXYCODONE; UNCLASSIFIED DRUG; NARCOTIC ANALGESIC AGENT;

ADULT; AGED; ANALGESIA; ARTICLE; CANCER PAIN; CANCER PATIENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NUTRITION RISK SCREENING 2002; NUTRITIONAL STATUS; RATING SCALE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; COMPLICATION; DRUG EFFECTS; MIDDLE AGED; NEOPLASMS; PAIN; PAIN MEASUREMENT; SEVERITY OF ILLNESS INDEX; TRANSDERMAL PATCH; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; FEMALE; FENTANYL; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NUTRITIONAL STATUS; PAIN; PAIN MANAGEMENT; PAIN MEASUREMENT; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TRANSDERMAL PATCH;

EID: 84899842466     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b13-00717     Document Type: Article

References (12)

1. Muijsers RB, Wagstaff AJ. Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs, 61, 2289-2307 (2001).
2. Ahmedzai S, Brooks D, The TTS-Fentanyl Comparative Trial Group. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. J. Pain Symptom Manage., 13, 254-261 (1997).
3. Donner B, Zenz M, Strumpf M, Raber M. Long-term treatment of cancer pain with transdermal fentanyl. J. Pain Symptom Manage., 15, 168-175 (1998).
4. Solassol I, Caumette L, Bressolle F, Garcia F, Thézenas S, Astre C, Culine S, Coulouma R, Pinguet F. Inter- and intra-individual variability in transdermal fentanyl absorption in cancer pain patients. Oncol. Rep., 14, 1029-1036 (2005).
5. Yamamoto K, Kojima M, Iguchi H, Ohta T. Measurement of amount of fentanyl remaining in used patches: investigation of clinical factors affecting the remaining amounts in 4 patients. Yakugaku Zasshi, 128, 959-964 (2008), Japanese.
6. Chiba T, Kimura Y, Takahashi H, Tairabune T, Nagasawa Y, Mori K, Yonezawa Y, Sugawara A, Kawaguchi S, Kawamura H, Nishizuka S, Kudo K, Fujiwara K, Ikeda K, Wakabayashi G, Takahashi K. Influence of body fat in cancer patients on residual content of used fentanyl matrix patches. Palliative Care Research, 5, 206-212 (2010).
7. Tairabune T, Takahashi H, Chiba T, Sugawara A, Kimura Y, Kudo K, Wakabayashi G, Takahashi K. Effect of nutritional status on transdermal fentanyl absorption in cancer patients. Palliative Care Research, 7, 395-402 (2012).
8. Kondrup J, Rasmussen HH, Hamberg O, Stanga Z, Ad Hoc ESPEN Working Group. Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials. Clin. Nutr., 22, 321-336 (2003).
9. Kondrup J, Allison SP, Elia M, Vellas B, Plauth M, Educational and Clinical Practice Committee, European Society of Parenteral and Enteral Nutrition (ESPEN). ESPEN Guideline for nutrition screening 2002. Clin. Nutr., 22, 415-421 (2003).
10. Sarhill N, Mahmoud FA, Christie R, Tahir A. Assessment of nutritional status and fluid deficits in advanced cancer. Am. J. Hosp. Palliat. Care, 20, 465-473 (2003).
11. Ooi K, Mitani N, Numajiri S, Morimoto Y. Appropriate method for applying fentanyl patches. Jpn. Pharmacol. Ther., 36, 589-592 (2008), Japanese.
12. Heiskanen T, Mätzke S, Haakana S, Gergov M, Vuori E, Kalso E. Transdermal fentanyl in cachectic cancer patients. Pain, 144, 218-222 (2009).